Back to News
Market Impact: 0.3

Benjamin Graham Detailed Fundamental Analysis

CARTNDAQ
Company FundamentalsCorporate EarningsAnalyst Insights
Benjamin Graham Detailed Fundamental Analysis

Validea's analysis of MAPLEBEAR INC (CART) utilizing its Benjamin Graham-inspired 'Value Investor' model resulted in a 57% rating, indicating the stock does not strongly align with deep value investment criteria. While CART passed on certain balance sheet health metrics like current ratio and debt, it notably failed on core valuation metrics including Price/Earnings, Price/Book, and long-term EPS growth, suggesting it does not fit a traditional value investment profile despite its classification as a large-cap growth stock.

Analysis

Maplebear Inc. (CART) receives a non-committal 57% rating from Validea's Benjamin Graham-inspired 'Value Investor' model, indicating it does not align with the core tenets of this deep value strategy. The analysis reveals a clear divergence in the company's financial profile: while it demonstrates balance sheet health by passing criteria for its current ratio and low long-term debt relative to net current assets, it fundamentally fails on key valuation and growth metrics. Specifically, CART did not meet the model's thresholds for its Price-to-Earnings (P/E) ratio, Price-to-Book (P/B) ratio, and long-term EPS growth. This suggests that despite being a large-cap stock with acceptable sales and liquidity, its current market price is too high and its historical earnings growth is insufficient to qualify as an attractive investment under this rigorous value-oriented screen.

AllMind AI Terminal

AI-powered research, real-time alerts, and portfolio analytics for institutional investors.

Request a Demo

Market Sentiment

Overall Sentiment

moderately negative

Sentiment Score

-0.50

Ticker Sentiment

CART-0.50
NDAQ0.00

Key Decisions for Investors

  • Investors following a pure value or Graham-style discipline should view this as a negative signal, as CART's high valuation multiples and weak long-term EPS growth are disqualifying factors under this methodology.
  • Given the stock passes on balance sheet health but fails on valuation, investors should critically assess whether future growth catalysts can justify the premium price, as the current fundamentals do not offer a value-based margin of safety.
  • For growth-oriented investors, this report highlights a key risk: the stock is priced for future performance, not current value, and any failure to deliver on high growth expectations could lead to a significant price correction.